{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:56:38Z","timestamp":1790808998767,"version":"4.1.0"},"reference-count":39,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,7]]},"abstract":"<jats:p>\n                    Tafenoquine is an 8-aminoquinoline under investigation for the prevention of relapse in\n                    <jats:italic>Plasmodium vivax<\/jats:italic>\n                    malaria. This open-label, dose-escalation study assessed quantitatively the hemolytic risk with tafenoquine in female healthy volunteers heterozygous for the\n                    <jats:italic>Mahidol<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>487A<\/jats:italic>\n                    <\/jats:sup>\n                    glucose-6-phosphate dehydrogenase (G6PD)-deficient variant versus G6PD-normal females, and with reference to primaquine. Six G6PD-heterozygous subjects (G6PD enzyme activity 40\u201360% of normal) and six G6PD-normal subjects per treatment group received single-dose tafenoquine (100, 200, or 300 mg) or primaquine (15 mg \u00d7 14 days). All participants had pretreatment hemoglobin levels \u2265 12.0 g\/dL. Tafenoquine dose escalation stopped when hemoglobin decreased by \u2265 2.5 g\/dL (or hematocrit decline \u2265 7.5%) versus pretreatment values in \u2265 3\/6 subjects. A dose\u2013response was evident in G6PD-heterozygous subjects (\n                    <jats:italic>N<\/jats:italic>\n                    = 15) receiving tafenoquine for the maximum decrease in hemoglobin versus pretreatment values. Hemoglobin declines were similar for tafenoquine 300 mg (\u22122.65 to \u22122.95 g\/dL [\n                    <jats:italic>N<\/jats:italic>\n                    = 3]) and primaquine (\u22121.25 to \u22123.0 g\/dL [\n                    <jats:italic>N<\/jats:italic>\n                    = 5]). Two further cohorts of G6PD-heterozygous subjects with G6PD enzyme levels 61\u201380% (\n                    <jats:italic>N<\/jats:italic>\n                    = 2) and &gt; 80% (\n                    <jats:italic>N<\/jats:italic>\n                    = 5) of the site median normal received tafenoquine 200 mg; hemolysis was less pronounced at higher G6PD enzyme activities. Tafenoquine hemolytic potential was dose dependent, and hemolysis was greater in G6PD-heterozygous females with lower G6PD enzyme activity levels. Single-dose tafenoquine 300 mg did not appear to increase the severity of hemolysis versus primaquine 15 mg \u00d7 14 days.\n                  <\/jats:p>","DOI":"10.4269\/ajtmh.16-0779","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T03:00:38Z","timestamp":1500951638000},"page":"702-711","source":"Crossref","is-referenced-by-count":100,"title":["Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers"],"prefix":"10.4269","volume":"97","author":[{"given":"Ronnatrai","family":"Rueangweerayut","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mae Sot General Hospital, Mae Sot, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germana","family":"Bancone","sequence":"additional","affiliation":[{"name":"Shoklo Malaria Research Unit, Mahidol\u2013Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Harrell","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research and Development Ltd., Uxbridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Beelen","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supornchai","family":"Kongpatanakul","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg J.","family":"M\u00f6hrle","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Rousell","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research and Development Ltd., Uxbridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadeeja","family":"Mohamed","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research and Development Ltd., Uxbridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Qureshi","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research and Development Ltd., Uxbridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Narayan","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research and Development Ltd., Uxbridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nushara","family":"Yubon","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Miller","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, King of Prussia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois H.","family":"Nosten","sequence":"additional","affiliation":[{"name":"Shoklo Malaria Research Unit, Mahidol\u2013Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Luzzatto","sequence":"additional","affiliation":[{"name":"Istituto Toscano Tumori, Florence, Italy;"},{"name":"Department of Hematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Duparc","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture, Geneva, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg-Peter","family":"Kleim","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research and Development Ltd., Uxbridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Green","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research and Development Ltd., Uxbridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","series-title":"Adv Parasitol","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-397900-1.00001-3","article-title":"The global public health significance of Plasmodium vivax","volume":"80","author":"Battle","year":"2012"},{"key":"b2","series-title":"Malar J","first-page":"280","article-title":"Primaquine radical cure of Plasmodium vivax: a critical review of the literature","volume":"11","author":"John","year":"2012"},{"key":"b3","year":"2013"},{"key":"b4","series-title":"Lancet","first-page":"1020","article-title":"Single-dose radical cure of Plasmodium vivax: a step closer","volume":"383","author":"Price","year":"2014"},{"key":"b5","series-title":"Science","first-page":"484","article-title":"Enzymatic deficiency in primaquine-sensitive erythrocytes","volume":"124","author":"Alving","year":"1956"},{"key":"b6","series-title":"Blood","first-page":"3560","article-title":"Molecular basis of glutathione reductase deficiency in human blood cells","volume":"109","author":"Kamerbeek","year":"2007"},{"key":"b7","series-title":"Br J Haematol","first-page":"575","article-title":"Erythrocyte hemighosts: a hallmark of severe oxidative injury in vivo","volume":"50","author":"Chan","year":"1982"},{"key":"b8","series-title":"Semin Hematol","first-page":"1","article-title":"Pathophysiology of hemolysis in glucose-6-phosphate dehydrogenase deficiency","volume":"27","author":"Arese","year":"1990"},{"key":"b9","series-title":"PLoS Med","first-page":"e1001339","article-title":"G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map","volume":"9","author":"Howes","year":"2012"},{"key":"b10","series-title":"Science","first-page":"1546","article-title":"Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians","volume":"326","author":"Louicharoen","year":"2009"},{"key":"b11","series-title":"Science","first-page":"839","article-title":"Glucose-6-phosphate dehydrogenase deficient red cells: resistance to infection by malarial parasites","volume":"164","author":"Luzzatto","year":"1969"},{"key":"b12","series-title":"Malar J","first-page":"13","article-title":"Heterogeneous alleles comprising G6PD deficiency trait in West Africa exert contrasting effects on two major clinical presentations of severe malaria","volume":"15","author":"Shah","year":"2016"},{"key":"b13","series-title":"Blood","first-page":"4123","article-title":"Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone","volume":"120","author":"Pamba","year":"2012"},{"key":"b14","series-title":"Malar J","first-page":"212","article-title":"Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta)","volume":"10","author":"Dow","year":"2011"},{"key":"b15","series-title":"J Infect Dis","first-page":"1282","article-title":"Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand","volume":"180","author":"Walsh","year":"1999"},{"key":"b16","series-title":"Clin Infect Dis","first-page":"1095","article-title":"Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse","volume":"39","author":"Walsh","year":"2004"},{"key":"b17","series-title":"Lancet","first-page":"1049","article-title":"Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study","volume":"383","author":"Llanos-Cuentas","year":"2014"},{"key":"b18","series-title":"Malar J","first-page":"391","article-title":"G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests","volume":"12","author":"Domingo","year":"2013"},{"key":"b19","series-title":"Am J Hematol","first-page":"19","article-title":"Neonatal jaundice and molecular mutations in glucose-6-phosphate dehydrogenase deficient newborn infants","volume":"51","author":"Huang","year":"1996"},{"key":"b20","series-title":"Br J Haematol","first-page":"402","article-title":"Cytochemical determination of heterozygous glucose-6-phosphate dehydrogenase deficiency in erythrocytes","volume":"63","author":"Vogels","year":"1986"},{"key":"b21","series-title":"Br J Haematol","first-page":"331","article-title":"International Committee for Standardization in Haematology: recommended methods for red-cell enzyme analysis","volume":"35","author":"Beutler","year":"1977"},{"key":"b22","series-title":"Malar J","first-page":"115","article-title":"Effective and cheap removal of leukocytes and platelets from Plasmodium vivax infected blood","volume":"8","author":"Sriprawat","year":"2009"},{"key":"b23"},{"key":"b24","series-title":"Proc Natl Acad Sci USA","first-page":"17486","article-title":"Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity","volume":"110","author":"Rochford","year":"2013"},{"key":"b25","series-title":"Clin Infect Dis","first-page":"1336","article-title":"Primaquine therapy for malaria","volume":"39","author":"Baird","year":"2004"},{"key":"b26","series-title":"Toxicology","first-page":"54","article-title":"Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: evaluation of eryptotic pathway","volume":"294","author":"Ganesan","year":"2012"},{"key":"b27","series-title":"J Lab Clin Med","first-page":"171","article-title":"The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character","volume":"44","author":"Dern","year":"1954"},{"key":"b28","series-title":"BMC Med","first-page":"203","article-title":"Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency","volume":"13","author":"Kheng","year":"2015"},{"key":"b29","series-title":"Dis Markers","first-page":"635670","article-title":"Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia","volume":"2015","author":"Barcellini","year":"2015"},{"key":"b30","series-title":"J Pharmacol Exp Ther","first-page":"509","article-title":"Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline","volume":"297","author":"Bolchoz","year":"2001"},{"key":"b31","series-title":"Adv Parasitol","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/B978-0-12-407826-0.00004-7","article-title":"G6PD deficiency: global distribution, genetic variants and primaquine therapy","volume":"81","author":"Howes","year":"2013"},{"key":"b32","series-title":"Br J Haematol","first-page":"469","article-title":"G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications","volume":"164","author":"Luzzatto","year":"2014"},{"key":"b33","series-title":"Malar J","first-page":"289","article-title":"Evaluation of the phenotypic test and genetic analysis in the detection of glucose-6-phosphate dehydrogenase deficiency","volume":"12","author":"Nantakomol","year":"2013"},{"key":"b34","year":"2011"},{"key":"b35","series-title":"Am J Trop Med Hyg","first-page":"854","volume":"91","author":"LaRue","year":"2014"},{"key":"b36","author":"Beutler","year":"1984"},{"key":"b37","series-title":"Br J Haematol","first-page":"57","article-title":"A sensitive cytochemical staining method for glucose-6-phosphate dehydrogenase activity in individual erythrocytes. II. Further improvements of the staining procedure and some observations with glucose-6-phosphate dehydrogenase deficiency","volume":"60","author":"Van Noorden","year":"1985"},{"key":"b38","series-title":"Am J Hum Genet","first-page":"359","article-title":"Studies of glucose-6-phosphate dehydrogenase activity of individual erythrocytes: the methemoglobin-elution test for identification of females heterozygous for G6PD deficiency","volume":"17","author":"Gall","year":"1965"},{"key":"b39","series-title":"Sci Rep","first-page":"299","article-title":"A novel cytofluorometric assay for the detection and quantification of glucose-6-phosphate dehydrogenase deficiency","volume":"2","author":"Shah","year":"2012"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/97\/3\/article-p702.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/97\/3\/article-p702.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/97\/3\/article-p702.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T18:35:14Z","timestamp":1722450914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/97\/3\/article-p702.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,7]]},"references-count":39,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.16-0779","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727846714.793548621","asserted-by":"object"}]},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,7]]}}}